Yesterday, BioSyent reported its fourth quarter and fiscal 2014 results. For the year, the company earned $3.15-million on revenue of $12.21-million, a topline that was up 57% year-over-year.
“Two thousand fourteen marked our fifth consecutive year of greater than 50-per-cent top-line growth,” said CEO Rene Goehrum. “With four launch phase products and two in growth phase, we have set the stage for continued progress in 2015 and 2016. This includes three product launches in the last nine months. In addition, we have more new product opportunities in our negotiation funnel than we have ever had before.”
Curtis says the BioSyent’s fourth quarter results (the company earned $1.06-million on revenue of $3.05-million) were slightly ahead of his expectations. He notes that many of the company’s peers are up more than 25% year-to-date, while BioSyent has fallen more than 7% over the same period. He thinks this represents an opportunity.
“…we encourage investors that are particularly price sensitive to take another look,” said the analyst. “We are confident significant catalysts are on the horizon; management is actively pursuing a large funnel of opportunities with several candidates in late-stage negotiations.”
In a research update to client this morning, Curtis maintained his “Speculative Buy” rating and one year target price of $13.25 on BioSyent, implying a return of 19% at the time of publication.